SCHEMBL15030739

SCHEMBL15030739

CCOP(C)(=O)N1CCN(C(=O)CS)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
POLB P06746 1/20 0.40
HTT P42858 1/20 0.40
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
HPGD P15428 1/20 0.32
RECQL P46063 1/20 0.32
PKM P14618 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
KDM4E B2RXH2 1/20 0.31
TSHR P16473 1/20 0.31
MAPT P10636 3/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
GAA P10253 1/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15871580 0.89 ALDH1A1 (0.34) ALDH1A1SMN1; SMN2POLBHTT
SCHEMBL19981499 0.83 SMN1; SMN2 (0.35) ALDH1A1SMN1; SMN2POLBHTTMEN1
SCHEMBL15030738 0.81 L3MBTL1 (0.40) ALDH1A1SMN1; SMN2POLBHTTMEN1
SCHEMBL15443801 0.73 TSHR (0.37) MEN1KMT2ATSHRGAA
SCHEMBL14654989 0.72 TSHR (0.36) ALDH1A1POLBMEN1KMT2AKDM4E
SCHEMBL23347875 0.72
SCHEMBL11559490 0.72 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2POLBHTTMEN1
SCHEMBL28856427 0.72
SCHEMBL14654991 0.69 TSHR (0.33) ALDH1A1POLBMEN1KMT2AKDM4E
SCHEMBL15443902 0.68 KMT2A (0.56) ALDH1A1SMN1; SMN2POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2788487-B1 OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA SAREPTA THERAPEUTICS INC (US) 2018-04-04 EP disclosed
EP-2788488-B1 METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA SAREPTA THERAPEUTICS INC (US) 2018-03-21 EP disclosed
US-9682097-B2 Oligonucleotide analogues targeting human LMNA SAREPTA THERAPEUTICS, INC. (US) 2017-06-20 US disclosed
US-9326992-B2 Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA SAREPTA THERAPEUTICS, INC. (US) 2016-05-03 US disclosed
US-9161948-B2 Peptide oligonucleotide conjugates SAREPTA THERAPEUTICS, INC. (US) 2015-10-20 US disclosed
US-20140024698-A1 METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA SAREPTA THERAPEUTICS, INC. (US) 2014-01-23 US disclosed
WO-2013086444-A2 METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA SAREPTA THERAPEUTICS, INC. (US) 2013-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024698-A1 METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA LMNA, LMNB2, LMNB1 ALDH1A1 4254/4885SMN1; SMN2 16/4885POLB 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.